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ABSTRACT
Background: Reports continue to show that lifestyle modification is 
cornerstone in the management of type 2 diabetes mellitus (T2DM). 
However, lifestyle and cultural patterns vary significantly across 
communities thereby necessitating the need for tailored dietary 
interventions to achieve optimal glycemic control. Presently, few 
prospective studies in Nigeria demonstrate the potential effects of diet 
modification on cardiometabolic, inflammation and prothrombotic 
factors. This study therefore assessed the effects of a twelve- 
month dietary modification on cardiometabolic, inflammation and 
prothrombotic factors in individuals with T2DM.
Materials and Methods: Forty adults with T2DM were enrolled into 
this longitudinal study. They were placed on 20%, 30% and 50% total 
caloric intake obtained from protein, fat, and carbohydrate respectively 
and were followed up for 12 months. Adherence to the dietary 
modification was assessed using a surrogate index. Standard methods 
were used to measure the blood pressure and anthropometric indices. 
Lipid profile, fasting plasma glucose (FPG), fibrinogen, plasminogen 
activator inhibitor- 1 (PAI- 1)], interleukin- 6 (IL- 6) and interleukin- 10 
(IL- 10) were measured using spectrophotometric methods and ELISA 







Wilcoxon signed-rank test and Spearman correlation as appropriate. P-
value less than0.05 was considered as statistically significant.
Results: There were no significant changes in the mean body weight,
body mass index (BMI), hip circumference (HC), waist-hip ratio,
systolic (SBP) and diastolic (DBP) blood pressure, FPG and low density
lipoprotein-cholesterol (LDL-C) at 6 months and 12 months compared
with the baseline. However, the mean levels of high density
lipoprotein-cholesterol (HDLc) was significantly elevated while the
mean waist circumference (WC) and waist- to-height ratio (WHtR)
were significantly reduced at 12- month compared with baseline. 
Interleukin- 10 (IL- 10) level was significantly higher at 6months 
compared with the baseline but reduced significantly at 12- month 
compared with the 6- month level. Unexpectedly, there was significant 
progressive rise in the median level of fibrinogen at 6- month and 
12- month compared with the baseline. Similarly, plasminogen 
activator inhibitor- 1 (PAI- 1) levels at 6- month and 12- month were 
significantly higher compared with the baseline.
Conclusion: It could be concluded from this study that twelve months 
of dietary modification improved central adiposity and high density 
lipoprotein- cholesterol but could not halt prothrombosis.
Keywords: Central adiposity, Dietary intervention, Inflammation, Prothrombosis, Type 2 diabetes mellitus.
INTRODUCTION
Diabetes mellitus is a global public health problem 
as its prevalence continues to rise worldwide. The 
International Diabetes Federation (IDF) reported 
that 463 million adults live with diabetes in the year 
2019 and estimated that by 2045, it will be around 
700 million.1 Of the adults living with diabetes, 79% 
live in low- and middle- income countries. In 2015, 
there were 1,702,900 cases of diabetes in Nigeria.2
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Reports have shown that type 2 diabetes mellitus 
(T2DM) constitutes about 90 to 95% of all diabe-
tes. This has been attributed to rapid cultural and 
social changes, ageing, increased urbanization, 
dietary changes, reduced physical activity and other 
unhealthy lifestyle and behavioural patterns.3,4
T2DM is a major cause of morbidity and prema-
ture mortality hence, a holistic approach to T2DM 
care is usually advocated.5 An important compo-
nent of T2DM care is dietary management which 
is based on the principle of healthy eating in the 
context of social, cultural and psychological influ-
ences on food choices.6 The goals of dietary manage-
ment in diabetes care are diverse. These include 
promotion and support of healthful eating patterns 
with emphasis on a variety of nutrient dense foods 
in appropriate portion sizes in order to improve 
overall health; addressing individual nutrition 
needs based on personal and cultural preferences, 
health literacy and numeracy, access to health-
ful food choices, willingness and ability to make 
behavioural changes, as well as barriers to change; 
maintenance of the pleasure of eating by provid-
ing non- judgmental messages about food choices; 
and provision of practical tools for day- to- day 
meal planning rather than focusing on individual 
macronutrients, micronutrients or single foods. 
These goals will help in achieving and maintaining 
body weight goals, attaining individualized glyce-
mic, blood pressure, and lipid goals, and prevention 
or delay of complications of diabetes.4- 7
Several studies have shown that healthy dietary 
habits and regular exercise are beneficial in the 
prevention and management of T2DM- related 
morbidity and mortality.8- 10 However, lifestyle and 
cultural patterns vary significantly, across and 
even within communities. To achieve effectiveness, 
acceptability and sustainability therefore, dietary 
interventions should be tailored according to regional 
and ethnic differences.11,12 We have previously shown 
that 6 – 12 months of dietary modification resulted 
in substantial cardiometabolic, inflammatory and 
prothrombotic improvements in adults with meta-
bolic syndrome (MS).14 This study was therefore 
designed to find out if the dietary modification that 
resulted in improved cardiometabolic, inflammatory 
and prothrombotic profile in adults with MS would 
result, when used in conjunction with the regular 
antidiabetic medications, in meaningful changes in 
markers of glycaemia, blood pressure, lipid, inflam-
mation and prothrombosis in adults with T2DM.
MATERIALS AND METHODS
Study participants
A total of 40 adults with T2DM attending the 
Endocrinology Clinic, Medical Outpatient Unit, 
University College Hospital, Ibadan were enrolled 
into this longitudinal study using convenient 
sampling. The patients were participants in a study 
titled “Risk Assessment of Type 2 Diabetes melli-
tus and Dementia in Nigerians with Metabolic 
Syndrome”.15 The patients were diagnosed using the 
World Health Organization criteria as venous fast-
ing plasma glucose (FPG) value of ≥ 7.0 mmol/L 
(126 mg/dl), or random plasma glucose value of 
≥  11.1 mmol/L (200 mg dl/l), or plasma glucose 
value of ≥ 11.1 mmol/L (200 mg/dl) 2 hours after 
a 75g oral load.3 The study participants were not 
newly diagnosed and were not on statins. A large 
proportion of the patients were on oral anti- diabetic 
drugs (mainly metformin and glibenclamide and 
pioglitazone hydrochloride) of different dosage 
while only a few were on insulin.
Ethical consideration
Ethical approval was obtained from the University 
of Ibadan/University College Hospital (UI/UCH) 
Joint Ethics Committee. Also, written informed 
consent was obtained from each participant before 
enrolment into the study.
Inclusion and exclusion criteria
The study participants were adults with diabetes 
mellitus who were 18 years or older and had been 
attending the Clinic for at least 3 months. Patients 
who were <18 years, critically ill, pregnant and 
those that did not give informed consent were 
excluded from the study.
Dietary prescription
The dietary prescription was as described previ-
ously.14 Briefly, a Principal Dietician had a compre-
hensive consultation with all the study participants. 
The need for behavioural change such as dietary 
modification and different cooking methods were 
explicitly discussed. Individual dietary intake was 
assessed using a 24- hour dietary recall. Based on 
the information provided by the patients which 
showed that their daily caloric intake was largely 
(approximately 70%) carbohydrate based, the total 
caloric intake obtained from protein, total fat and 
carbohydrate was calculated and pegged at 20%, 
30% (including 14% polyunsaturated fat) and 50% 
respectively. The dietary prescription was struc-
tured following the Therapeutic Life- Style Changes 
diet recommendation.16 Verbal and written instruc-
tions containing list of recipes and quantities of 
different foods to be consumed to meet the desired 
dietary requirement were provided to each partici-
pant. The participants were advised to adhere to the 
dietary advice in addition to the use of oral anti-
diabetic drugs or insulin as recommended by their 
Physicians.
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Follow up of the participants
Each participant was seen monthly for 12 months 
by the Dietician and information on compliance 
was obtained using a 24- hour dietary recall. Clinical 
assessment of compliance was done by calculating 
the waist- to- height ratio (WHtR); an index of 
dietary adherence.17
Sample collection
After an overnight fast of about 10 - 12 hr, 15 ml 
of blood was obtained from each participant at 
baseline (before the commencement of dietary 
modification), 6 months and 12 months (post- -
dietary modification). Reminder telephone calls 
were made to each participant prior to their 
scheduled 6- and 12- months visits. Samples were 
dispensed into appropriate bottles and serum and 
plasma samples obtained were stored at - 20°C until 
analysed.
Measurement of anthropometric indices
The height of each participant was measured in 
meters with subjects standing bare footed on a 
stadiometer. The body weight was taken with an 
Omron (Bf 400) weighing scale placed on a flat 
surface while the participants wore light clothing 
with no shoes. The reading was recorded in kilo-
gram (kg). Thereafter, the body mass index (BMI) 
was calculated as the ratio of body weight (kg) to 
the square of height (m). Waist circumference was 
measured using a measuring tape placed between 
the lower rib margins and the iliac crest while the 
hip circumference was measured at the widest 
circumference of the hip over light clothing, using 
a non- stretchable measuring tape. The waist- hip 
ratio (WHR) was calculated as the ratio of waist 
circumference to the hip circumference while 
the waist- height ratio (WHtR) was calculated by 
dividing the waist circumference by the height. 
The percentage body fat was measured using the 
bioelectrical impedance method (Omron BF 400, 
UK). The values were recorded in %.
Blood pressure measurement
The diastolic and systolic blood pressure readings 
were taken twice with the use of mercury sphyg-
momanometer by a Physician after the patients 
have rested for at least ten minutes and in a sitting 
position. The mean values were recorded in mmHg 
according to the standard procedures.
Laboratory analyses
Determination of fasting plasma levels of glucose, 
total cholesterol (TC), triglyceride (TG) and high 
density lipoprotein cholesterol (HDLc) were 
determined using enzymatic method while the 
plasma level of low density lipoprotein cholesterol 
(LDLc) was calculated using the Frieldwald et al.18 
formula. Serum concentrations of interleukins 
6- and - 10 (IL- 6, IL- 10), plasminogen activator 
inhibitor- 1 (PAI- 1) and fibrinogen were deter-
mined using sandwich ELISA (Boster Biological 
Technology Co., Inc, USA and Assaypro LLC, 
USA).
Statistical analysis
Statistical analysis was carried out using SPSS soft-
ware, version 17.0. Histogram was used to assess 
the Gaussian distribution of all the continuous 
variables. Values are reported as mean ± standard 
deviation or median (interquartile range) as appro-
priate. Differences in means/medians were deter-
mined using paired Student’s t- test or Wilcoxon 
signed- rank test as appropriate. The relationship 
between all the variables was assessed using 
Spearman correlation. P- values less than 0.05 were 
considered as statistically significant.
RESULTS
Changes in anthropometric, clinical and 
cardiometabolic indices of the study participants 
after 12 months of dietary modification are shown 
in Table 1. Only HDLc had progressive rise in 
concentration from baseline through 12 months. 
There were no significant changes in the mean 
body weight, BMI, HC, waist- hip ratio, systolic and 
diastolic blood pressure, fasting plasma glucose 
(FPG) and LDLc at 6 months and 12 months 
compared with the baseline. The mean levels of 
HDLc, TC and TG were significantly elevated 
while WC and WHtR were significantly reduced at 
12- month compared with baseline. Also, HDLc and 
TC were significantly elevated while body fat was 
significantly reduced at 12- month compared with 
6- month.
The median level of IL- 10 was significantly 
higher at 6- month compared with the baseline 
but reduced significantly at 12- month (paralleling 
the baseline) compared with the 6- month level. 
Unexpectedly, there was significant progressive rise 
in the median level of fibrinogen at 6- month and 
12- month compared with the baseline. Similarly, 
the median levels of PAI- 1 at 6- month and 
12- month were significantly higher compared with 
the baseline (Table 2).
As shown in Table 3, WC had significant positive 
correlation with body weight, BMI, HC, waist- hip 
ratio and body fat. Also, HDLc had significant 
positive correlation with IL- 10, TC and PAI- 1. In 
addition, SBP and DBP had significant positive 
correlation with BMI, HC and body fat.
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Table 1  Anthropometric, Clinical and Cardiometabolic Indices in T2DM Patients at Baseline, 6 months and 
12 months
Baseline (n = 40) 6- month (n = 40) 12- month (n = 40)
Body weight (kg) 67.8 ± 12.0 67.1 ± 11.8 67.4 ± 11.5
BMI (kg/m2) 25.2 ± 3.5 24.8 ± 3.4 24.9 ± 3.4
Waist circumference (cm) 94.6 ± 9.1 90.5 ± 16.6 91.1 ± 9.3a†
Hip circumference (cm) 96.7 ± 7.6 96.9 ± 7.4 94.6 ± 11.3
Waist- Hip ratio 0.98 ± 0.06 0.97 ± 0.07 0.97 ± 0.12
WHtR 58.0 ± 5.4 55.3 ± 10.2 55.8 ± 6.3a†
Body fat (%) 32.4 ± 11.7 29.7 ± 8.8 31.3 ± 8.1b† 
Systolic BP (mmHg) 124.4 ± 16.7 127.5 ± 20.4 130.3 ± 19.9
Diastolic BP (mmHg) 75.1 ± 6.8 75.0 ± 9.3 74.0 ± 9.0 
FPG (mg/dl) 128.1 ± 47.8 112.2 ± 44.2 114.7 ± 39.1
TC (mg/dl) 151.2 ± 45.1 155.2 ± 38.1 171.1 ± 42.2 a‡, b‡
TG (mg/dl) 72.6 ± 30.4 73.2 ± 29.1 84.6 ± 35.9a‡
HDLc (mg/dl) 37.0 (22.5 – 48.3) 47.0 (37.3 – 55.5)a‡ 53.5 (38.3 – 91.8)a‡, b‡ 
LDLc (mg/dl) 100.5 ± 38.7 89.3 ± 33.3 90.9 ± 40.5
Values are in mean ± standard deviation or median (interquartile range), n = number of participants, T2DM = type 2 diabetes mellitus, a†significantly reduced when 
compared with baseline, a‡significantly increased compared with baseline, b†significantly reduced compared with 6- month, b‡significantly increased compared with 
baseline, BP = blood pressure, BMI = body mass index, WC = waist circumference, HC = Hip circumference, WHtR = waist- to- height ratio, FPG = fasting plasma 
glucose, TC = total cholesterol, TG = triglyceride, HDLc= high density lipoprotein cholesterol, LDLc = low density lipoprotein cholesterol.
Table 2  Indices of Inflammation and Prothrombosis in T2DM Patients at Baseline, 6 months and 12 months
Baseline (n = 40) 6- month (n = 40) 12- month (n = 40)
IL- 6 (pg/ml) 0.74 (0.74 – 49.8) 27.1 (0.74 – 75.3) 13.0 (0.74 – 72.7) 
IL- 10 (pg/ml) 90.2 (59.6 – 171.1) 151.6 (120.9 – 271.9)a‡ 93.0 (48.5 – 152.9)b†
Fibrinogen (µg/ml) 1519.9 (1075.5 – 2361.4) 3298.2 (1845.6 – 5039.0)a‡ 7370.2 (5237.8 – 11714.2)a‡, b‡ 
PAI- 1 (ng/ml) 4.9 (4.6 – 5.0) 5.2 (5.0 – 5.3)a‡ 5.2 (5.0 – 5.2)a‡ 
Values are in median (interquartile range), n = number of participants, T2DM = type 2 diabetes mellitus, a†significantly reduced when compared with baseline, 
a‡significantly increased compared with baseline, b†significantly reduced compared with 6- month, b‡significantly increased compared with baseline, IL = interleukin, 
PAI = plasminogen activator inhibitor
Table 3  Correlation between Selected Cardiometabolic Factors and Blood Pressure at Baseline
WC FPG TG HDLc SBP DBP
Body weight 0.631, 0.000** 0.171, 0.291 0.099, 0.543 - 0.106, 0.517 0.291, 0.072 0.340, 0.034*
BMI 0.758, 0.000** 0.181, 0.264 0.196, 0.225 - 0.197, 0.223 0.428, 0.007** 0.401, 0.011*
HC 0.717, 0.000** 0.193, 0.274 0.041, 0.819 - 0.029, 0.869 0.427, 0.012* 0.472, 0.005**
Waist- hip ratio 0.573, 0.000** 0.125, 0.481 0.295, 0.090 0.145, 0.414 - 0.069, 0.698 - 0.301, 0.084
Body fat 0.445, 0.008** 0.059, 0.717 0.283, 0.076 - 0.214, 0.185 0.380, 0.017* 0.400, 0.012*
IL- 10 - 0.002, 0.991 0.040, 0.806 0.084, 0.606 0.413, 0.008** - 0.058, 0.726 - 0.297, 0.067
IL- 6 - 0.032, 0.859 0.173, 0.287 - 0.053, 0.747 0.160, 0.325 0.041, 0.804 - 0.086, 0.602
Fibrinogen - 0.061, 0.730 - 0.011, 0.948 0.169, 0.297 - 0.083, 0.611 - 0.193, 0.239 - 0.103, 0.534
PAI- 1 - 0.025, 0.890 0.212, 0.190 0.051, 0.755 0.327, 0.039* 0.044, 0.792 0.149, 0.365
TC - 0.028, 0.876 0.212, 0.190 0.007, 0.968 0.555, 0.000** 0.054, 0.745 0.160, 0.330
LDLc 0.069, 0.698 0.190, 0.241 - 0.061, 0.708 0.284, 0.075 - 0.037, 0.824 0.174, 0.288
Values are reported as r- value, p- value, **significantly correlated at 0.01 level, *significantly correlated at 0.05 level, BMI = body mass index, WC = waist circumference, 
SBP = systolic blood pressure, DBP = diastolic blood pressure, HC = Hip circumference, FPG = fasting plasma glucose, TC = total cholesterol, TG = triglyceride, 
HDLc= high density lipoprotein cholesterol, LDLc = low density lipoprotein cholesterol, IL = interleukin, PAI = plasminogen activator inhibitor.
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DISCUSSION
Lifestyle modification is cornerstone in the 
management of T2DM.19 It is essential for opti-
mal glycemic control and for preventing diabetes 
complications.20 However, the benefit accrued to 
lifestyle modification in T2DM care is usually 
not optimized due to patients’ poor adherence. 
It has been reported in several studies that poor 
adherence to healthy lifestyle recommendations 
is prevalent amongst patients with T2DM.20- 24 
This has unfortunately, been resulting in frequent 
hospitalisations with its attendant high health 
care costs.25
The observed reduction in the mean WC at 
6- month and at 12- month compared with baseline 
indicates reduction in central adiposity, which 
could be as a result of redistribution of body fat. 
A similar observation was reported by Eriksson 
and Lindgärde26 which showed that significant 
reduction in anthropometric indices was achieved 
following dietary modification.
Reports have shown that WHR and WHtR are 
better indices of central adiposity than WC.27,28 
The observed progressive reduction in the mean 
WHtR post- dietary modification corroborates the 
observed reduction in WC and may thus suggest 
that there was an appreciable adherence to the 
dietary modification. Martínez- González et  al.17 
reported an inverse association between WHtR and 
adherence to the Mediterranean diet.
Intentional weight loss is associated with a 
significant reduction in all- cause mortality in 
overweight and obese T2DM patients.19,29 The 
Look AHEAD (Action for Health in Diabetes) 
trial showed that intensive lifestyle intervention 
(ILI) facilitates significant weight loss over a short 
and extended period of time.30- 32 In this study, 
reductions in the mean body weight and BMI were 
not significant. This observation contradicts the 
report of Eriksson and Lindgärde26 and could be 
due to disparities in selection of participants in 
the different studies. In this study, the participants 
were gender- matched (20 males and 20 females) 
and were not obese but were slightly overweight 
(25.2 kg/m2). It could therefore, imply that diet- 
associated reduction in body weight and BMI is 
substantial in T2DM patients that are considerably 
overweight or obese.
Modest reduction in body weight is associ-
ated with improvements in lipid profile, insulin 
level, and glycemic control.33,34 This supports 
the observed increase in HDLc at 6- month and 
12- month post- dietary modification. This obser-
vation indicates improved cardioprotection follow-
ing the short term dietary modification. This is 
further buttressed by the observed reduction, 
albeit insignificant, in LDLc level, a component of 
non- HDLc, post dietary modification. nonHDLc 
(defined as total cholesterol minus HDLc) which 
denotes the cholesterol contained in VLDL, IDL, 
and LDL particles is considered a better predictor 
of cardiovascular events and mortality in patients 
with DM.35,36 Unfortunately, the mean level of TG 
was significantly elevated at 12- month compared 
with baseline. This observation indicates that there 
is the need for downward review of the percentage 
total caloric intake obtained from total fat (30%) to 
optimize the observed associated increase in HDLc 
level.
A considerable weight loss of >5% has been 
reported to be necessary for any substantial 
improvement on blood pressure.37 A non- significant 
decrease in systolic and diastolic BP has been 
reported in T2DM patients following 12  months 
of lifestyle intervention.38- 44 These earlier reports 
support the observed non- significant changes 
in SBP and DBP in this study. This observation, 
together with other previous reports, probably 
indicates that dietary management might not be an 
effective strategy in the control of BP especially, in 
non- obese diabetics. It can thus be suggested that 
lifestyle interventions be used as adjunct to phar-
macotherapy in the control of BP.
Disordered inflammatory and prothrombosis 
pattern has been reported in T2DM patients.45 
Similarly, insulin- sensitizing drugs such as 
thiazolidinediones have been shown to possess 
anti- inflammatory and pro- adipogenic effects.46 
A major limitation of this study was the enrol-
ment of T2DM patients on insulin and oral 
anti- hyperglycaemic drugs instead of drug- naïve 
T2DM patients that will be placed on nutritional 
management only. These drugs can modulate the 
inflammatory homeostasis and obscure the effect 
of dietary modification. The influence of drugs 
might be responsible for the observed higher 
levels of fibrinogen and PAI- 1 at 6- months and 
12- months compared with baseline. Similarly, 
IL- 10 which was significantly higher at 6- months 
reduced significantly at 12- months. These observa-
tions, which cannot be explained presently, could 
be due to the influence of some of the drugs (since 
most diabetics are on poly- pharmaceutical ther-
apy) being taken by the participants on the acute 
phase reactants and inflammatory cytokines.
Considering the relationship between the 
parameters, HDLc had significant positive correla-
tion with IL- 10 and TC. This is in line with the 
report of van Exel et  al.47 IL- 10 and HDLc have 
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been reported to have potent anti- inflammatory 
and anti- atherosclerosis properties. The positive 
correlation between HDLc and TC indicates that 
there is corresponding increase in total cholesterol 
as HDLc increases. This is not surprising as HDLc is 
a component of the TC. In addition, SBP and DBP 
had significant positive correlation with BMI, HC 
and body fat. This observation is not unexpected as 
it is widely established that hypertension is linked 
with overweight and obesity.48,49
It could be concluded from this study that twelve 
months of dietary modification improved central 
adiposity and HDLc but could not halt prothrom-
bosis. To fully understand the impact of dietary 
modification on inflammation and prothrombosis 
in T2DM, studies with strict adherence to dietary 
modification over an extended period of time is 
suggested in drug- naïve individuals with T2DM.
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